Pfizer to Acquire ReViral for Up to $525M, Expanding RSV Pipeline
Pfizer has agreed to acquire ReViral, a developer of antiviral therapeutics targeting respiratory syncytial virus (RSV), for up to $525 million, the companies said today, in a deal designed to meet the unmet need for RSV treatments by adding ReViral’s infectious disease pipeline and R&D capabilities to those of the buyer.